Pfizer’s Palbociclib Doubles Progression-Free Survival in Breast Cancer Trial

Pfizer’s Palbociclib Doubles Progression-Free Survival in Breast Cancer Trial
shutterstock_224672638An experimental drug known as palbociclib, developed by Pfizer, Inc. and tested at the Revlon/UCLA Women's Cancer Research Program in UCLA's Jonsson Comprehensive Cancer Center (JCCC), extended progression-free survival of women with breast cancer by twice that achieved in women treated without palbociclib in a phase 2 clinical trial. The news was presented at the American Association for Cancer Research Annual Meeting held in San Diego. "By combining the test drug, palbociclib, with the standard drug letrozole, we demonstrated a dramatic and clinically meaningful effect on progression-free survival in women with ER+ advanced breast cancer," said Dr. Richard S. Finn, associate professor of medicine at JCCC, in a news release from UCLA. "We are gratified and excited that these results confirm the preclinical work we began at the Translational Lab." Pfizer developed palbociclib (PD 0332991) in preclinical work using a panel of human breast cancer cells. Notably, the drug was especially effective against estrogen receptor positive (ER+) breast cancer cells. Additionally, Dr. Dennis Slamon, professor of medicine at JCCC and director of the Revlon/UCLA Women's Cancer Program, conducted research in his lab at the Translational Oncology Research Laboratory. These preclinical investigations led to a phase 1 clinical trial with collaborations between JCCC and Pfizer and led
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.